Inactive Instrument

News Cyclacel Pharmaceuticals Inc Nasdaq

Equities

US23254L1089

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Jun. 26	Sector Update: Health Care Stocks Softer Late Afternoon	MT
Jun. 26	Sector Update: Health Care Stocks Lower in Afternoon Trading	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Softer Late Afternoon	Jun. 26	MT
Sector Update: Health Care Stocks Lower in Afternoon Trading	Jun. 26	MT
Cyclacel Receives Notice of European Patent Grant for Plogosertib; Shares Rise	Jun. 26	MT
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions	Jun. 26	CI
Cyclacel Pharmaceuticals : A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma	Jun. 03	PU
Cyclacel Pharmaceuticals, Inc. Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib?s Potential as Precision Medicine for Cancer	Jun. 03	CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Transcript : Cyclacel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024	May. 14
Earnings Flash (CYCC) CYCLACEL PHARMACEUTICALS Posts Q1 Revenue $29,000	May. 14	MT
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results	May. 09	AQ
Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding	May. 01	CI
Top Midday Gainers	Apr. 30	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of FOMC Meeting	Apr. 30	MT
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $8.000001 million in funding	Apr. 29	CI
Cyclacel Pharmaceuticals Withdraws Securities Offering SEC Filing	Apr. 29	DJ
Cyclacel Pharmaceuticals : April 2024 Corporate Presentation	Apr. 02	PU
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer	Apr. 01	CI
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 20	AQ
Transcript : Cyclacel Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024	Mar. 19
Earnings Flash (CYCC) CYCLACEL Posts Q4 Revenue $31,000	Mar. 19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cyclacel Pharmaceuticals Inc Nasdaq

Equities

US23254L1089

Summary

Filters